Equinor ASA (EQNR)

Total Liabilities

$97.77B

Quarterly · Period ending: · USD

EQNR logo

EQNR Total Liabilities

Latest reported$97.77B
EQNR Quarterly Total Liabilities ($18.91B → $97.77B)
High-resolution chart · PNG

EQNR total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Equinor ASA Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
97,767,000,000
97,512,000,000
91,229,940,000
95,250,630,000
97,120,793,000
92,032,000,000
88,761,000,000
90,732,000,000
90,442,000,000
87,118,000,000
95,080,000,000
90,697,000,000
90,328,000,000
95,321,000,000
104,032,000,000
109,863,000,000
110,740,000,000
115,668,000,000
108,096,000,000
99,739,000,000
90,218,000,000
86,452,000,000
90,918,000,000
80,323,000,000
79,172,000,000
67,803,000,000
78,702,000,000
76,109,000,000
78,946,000,000
77,196,000,000
69,518,000,000
74,113,000,000
73,335,000,000
72,833,000,000
71,215,000,000
72,883,000,000
72,585,000,000
71,110,000,000
69,431,000,000
73,501,000,000
70,798,000,000
70,604,000,000
69,575,584,384
73,926,967,472
75,776,258,552
79,672,430,071
81,400,650,720
86,490,562,056
87,345,644,785
88,100,372,149
87,082,060,372
81,848,371,605
78,986,783,415
80,919,226,004
83,203,777,072
81,721,153,712
79,129,575,508
85,386,885,896
80,996,515,212
78,551,799,826
77,423,544,868
76,636,342,472
70,865,808,229
69,549,826,593
62,182,023,048
62,193,012,047
62,592,774,743
64,928,498,529
56,460,377,264
53,926,217,339
52,072,000,000
62,040,000,000
69,289,000,000
66,332,000,000
55,994,000,000
40,945,000,000
36,576,000,000
34,630,000,000
30,761,000,000
32,981,000,000
31,289,000,000
31,523,000,000
26,205,000,000
28,452,000,000
25,950,000,000
27,154,000,000
26,777,000,000
25,714,000,000
22,209,000,000
22,658,000,000
22,552,000,000
21,435,000,000
19,462,000,000
22,197,000,000
21,149,000,000
19,078,000,000
18,108,000,000
16,837,000,000
16,297,000,000
19,722,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.